Generic Product News

JULY 19, 2013

Zenatane (Isotretinoin Capsules USP)

Marketed by: Dr. Reddy’s Laboratories
Compare to: Accutane (Hoffmann-La Roche)
Indication: Dr. Reddy’s Laboratories has launched Zenatane (isotretinoin capsules USP), a therapeutically equivalent generic version of Accutane. To avoid a high risk of birth defects, Zenatane is not indicated for female patients who are or may become pregnant, and it is approved for marketing only under a restricted FDA-approved distribution program called iPLEDGE. Zenatane should be discontinued if pregnancy occurs, and patients should be referred to an obstetrician-gynecologist experienced in toxicity.
Dosage Form: Capsules: 10 mg, 20 mg, 40 mg
For More Information:

Trospium Chloride Extended-Release Capsules

Marketed by: Perrigo Company
Compare to: Sanctura XR (Allergan)
Indication: Perrigo Company has received final approval for the generic version of Sanctura XR. It is indicated for the treatment of overactive bladder symptoms, including urge urinary incontinence, urgency, and urinary frequency. Trospium Chloride Extended-Release Capsules are available as a once-daily, 60-mg dose that should be taken in the morning at least 1 hour before eating. The product has begun shipping.
Dosage Form: Capsules: 60 mg
For More Information:

Sildenafil Tablets 
Marketed by: Teva Pharmaceuticals
Compare to: Revatio (Pfizer Inc)
Indication: Teva Pharmaceuticals is pleased to announce the introduction and availability of sildenafil tablets. This product is AB rated and bioequivalent to Revatio Tablets. It is indicated for the treatment of pulmonary arterial hypertension in adults to improve exercise ability and delay clinical worsening. The recommended dose is a 20-mg tablet 3 times a day, taken 4 to 6 hours apart. Sildenafil tablets are available in 20-mg strength, in bottle sizes of 90.
Dosage Form: Tablets: 20 mg
For More Information:

Desvenlafaxine Base Extended-Release Tablets

Marketed by: Ranbaxy Pharmaceuticals, Inc
Compare to: Pristiq (Pfizer Inc)
Indication: Ranbaxy Pharmaceuticals Inc entered an in-licensing agreement with Alembic Pharmaceuticals Limited to exclusively market desvenlafaxine base extendedrelease tablets in the United States. Alembic Pharmaceuticals Limited sponsored the new drug application for the product and is the manufacturer. The product is indicated for the treatment of major depressive disorder and is bioequivalent to Pfizer Inc’s Pristiq.
Dosage Form: Tablets: 50 mg, 100 mg
For More Information:

Pharmacy Times Strategic Alliance

Pharmacist Education
Clinical features with downloadable PDFs

Personalize the information you receive by selecting targeted content and special offers.